BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
Priority Review
ENJAYMO (sutimlimab-jome) by Recordati is classical complement pathway inhibitors [moa]. Approved for cold agglutinin disease. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENJAYMO (sutimlimab-jome) is a classical complement pathway inhibitor administered via intravenous injection for the treatment of Cold Agglutinin Disease (CAD). It works by blocking the C1s enzyme in the classical complement cascade, reducing hemolysis and related symptoms in this rare blood disorder. The drug represents a targeted immunological approach to an orphan disease with limited prior therapeutic options.
$0.001BPart D
PeakProduct is in peak commercial phase with modest Part D spending (~$1M in 2023), indicating early adoption phase in a niche orphan indication with potential for revenue growth as awareness increases.
Mechanism of Action
Classical Complement Pathway Inhibitors
Pharmacologic Class:
Classical Complement Pathway Inhibitor
Indications (1)
Career Relevance
ENJAYMO is a niche orphan product with limited publicly visible job postings, reflecting its small commercial footprint and highly specialized sales/medical affairs requirements. Career roles on this product typically involve rare disease expertise, deep KOL relationships, and patient advocacy coordination.
Worked on ENJAYMO at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.